Masataka Sawaki

Summary

Affiliation: Nagoya University
Country: Japan

Publications

  1. doi request reprint Phase I/II study of intraoperative radiotherapy for early breast cancer in Japan
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Breast Cancer 19:353-9. 2012
  2. doi request reprint Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study
    Masataka Sawaki
    Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Breast Cancer 19:253-8. 2012
  3. ncbi request reprint High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Breast Cancer 13:172-8. 2006
  4. doi request reprint A phase I study of intraoperative radiotherapy for early breast cancer in Japan
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa ku 466 8550, Nagoya, Japan
    World J Surg 33:2587-92. 2009
  5. doi request reprint Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]
    Masataka Sawaki
    Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Jpn J Clin Oncol 41:709-12. 2011
  6. doi request reprint The effect of toremifene on lipid metabolism compared with that of tamoxifen in vitro
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, Nagoya, Japan
    Gynecol Obstet Invest 71:213-6. 2011
  7. ncbi request reprint Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Tumori 90:40-3. 2004
  8. ncbi request reprint Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience
    Keiko Furukawa
    Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
    Breast Cancer 13:329-33. 2006
  9. doi request reprint Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection
    Hideki Takada
    Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    World J Surg 35:1560-6. 2011
  10. doi request reprint Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients
    Masataka Sawaki
    Department of Surgery II, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Surg Today 40:831-5. 2010

Collaborators

Detail Information

Publications24

  1. doi request reprint Phase I/II study of intraoperative radiotherapy for early breast cancer in Japan
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Breast Cancer 19:353-9. 2012
    ..We have begun our study with the first step being a phase I-II study. This study was designed to identify the recommended dose and to test the feasibility of and tolerance to IORT in Japanese patients (UMIN000000918)...
  2. doi request reprint Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study
    Masataka Sawaki
    Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Breast Cancer 19:253-8. 2012
    ..But there are few data on trastuzumab in elderly patients. We evaluated the incidence of adverse events among an elderly population of trastuzumab-treated HER-2-positive breast cancer patients in adjuvant settings...
  3. ncbi request reprint High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Breast Cancer 13:172-8. 2006
    ..We have summarized a single-center experience involving IBC patients. Our objectives are to clarify molecular alterations of HER-2/neu and p53 in IBC and to investigate the prognostic factors...
  4. doi request reprint A phase I study of intraoperative radiotherapy for early breast cancer in Japan
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa ku 466 8550, Nagoya, Japan
    World J Surg 33:2587-92. 2009
    ..The present study was designed to identify the optimal intraoperative radiotherapy (IORT) dose for early breast cancer in Japanese women...
  5. doi request reprint Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]
    Masataka Sawaki
    Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Jpn J Clin Oncol 41:709-12. 2011
    ....
  6. doi request reprint The effect of toremifene on lipid metabolism compared with that of tamoxifen in vitro
    Masataka Sawaki
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, Nagoya, Japan
    Gynecol Obstet Invest 71:213-6. 2011
    ..TAM is known to increase intracellular triglyceride, but the action of TOR on lipid metabolism in vitro has not yet been determined. Aim: To compare the effect of TOR on lipid metabolism with that of TAM in vitro, using HepG2 cell lines...
  7. ncbi request reprint Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Tumori 90:40-3. 2004
    ..It became available in Japan in June 2001. This study focuses on the efficacy and safety of trastuzumab as a single agent in second-third line treatment of HER2/neu-overexpressing metastatic breast cancer...
  8. ncbi request reprint Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience
    Keiko Furukawa
    Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
    Breast Cancer 13:329-33. 2006
    ..Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer...
  9. doi request reprint Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection
    Hideki Takada
    Department of Breast and Endocrine Surgery, Nagoya University Hospital, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    World J Surg 35:1560-6. 2011
    ..The aim of this study was to clarify the LNM pattern in PTC patients based on our institution's experience with a consistent technique of bilateral neck dissection, and to consider the rational extent of lymph node dissection...
  10. doi request reprint Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients
    Masataka Sawaki
    Department of Surgery II, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Surg Today 40:831-5. 2010
    ..To evaluate the frequency and prognostic importance of neuroendocrine differentiation (NED) in Japanese breast cancer patients...
  11. doi request reprint Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor
    Yutaka Yamamoto
    Department of Breast and Endocrine Surgery, Kumamoto University, Japan
    Breast Cancer 17:254-60. 2010
    ..In this study, we investigated the efficacy and safety of toremifene (TOR, Fareston(®)), a selective estrogen receptor modulator (SERM)...
  12. ncbi request reprint Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Tumori 90:36-9. 2004
    ..We evaluated retrospectively the efficacy and toxicity of paclitaxel in patients with docetaxel-resistant metastatic breast cancer...
  13. doi request reprint Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer
    Masataka Sawaki
    Tokai Breast Cancer Clinical Research Group, Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, Aichi, Japan
    Breast 19:370-6. 2010
    ..Subgroup analysis suggests that ER/PgR negative tumors might be associated with pathological response in locally advanced breast cancer...
  14. ncbi request reprint Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors
    Sachi Morita
    Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi, 466 8560, Japan
    Invest New Drugs 30:1950-7. 2012
    ..Stable disease for ≥4 months was observed in six patients; however, there were no complete or partial responses. It is feasible to conclude that 20 mg/m(2) was the MTD and recommend as the starting dose for phase II clinical trials...
  15. ncbi request reprint The feasibility study of docetaxel in patients with anaplastic thyroid cancer
    Kenji Kawada
    Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan
    Jpn J Clin Oncol 40:596-9. 2010
    ..The median time to progression was 6 weeks (range, 1-50). Toxicity was tolerable. Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity...
  16. ncbi request reprint Nodular fasciitis of the breast
    Hironori Hayashi
    Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan
    Breast Cancer 14:337-9. 2007
    ..Histologically, the excised tumor was consistent with nodular fasciitis of the breast. Nodular fasciitis should be considered in the differential diagnosis of a mass suspicious for breast cancer...
  17. doi request reprint Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes
    Toyone Kikumori
    Department of Breast and Endocrine Surgery, Nagoya University Hospital, Showaku, Nagoya, Japan
    Breast Cancer Res Treat 113:435-41. 2009
    ..The effective targeting and cytocidal abilities of HML have been achieved using cell culture models. This study aimed to investigate feasibility of this modality for breast cancer treatment using tumor-bearing mouse models...
  18. ncbi request reprint Extravasation of pegylated-liposomal doxorubicin: favorable outcome after immediate subcutaneous administration of corticosteroids
    Ayako Mitsuma
    Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan
    Nagoya J Med Sci 74:189-92. 2012
    ..There were no serious complications at the extravasation site, such as tissue necrosis or severe pain, and only a transient erythema of the skin and desquamation remained after 2 months...
  19. doi request reprint Neuroendocrine tumor in the breast
    Hiroshi Ogawa
    Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8560, Japan
    Radiat Med 26:28-32. 2008
    ..Both of the tumors were resected, and a primary breast neuroendocrine tumor (solid neuroendocrine carcinoma) and peritoneal dissemination of the ovarian carcinoid tumor were diagnosed...
  20. ncbi request reprint Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A
    Shigeru Yoshida
    Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan
    Endocr J 56:545-51. 2009
    ..Total parathyroidectomy with autotransplantation at the time of primary surgery for MTC, i.e. total thyroidectomy with bilateral central neck dissection, is a feasible approach for managing the risk of hyperparathyroidism...
  21. ncbi request reprint Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result
    Takahiro Ito
    Department of Breast and Endocrine Surgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
    Surg Today 36:961-5. 2006
    ..To determine the incidence and importance of functioning tumors among incidentally discovered adrenal masses in the era of laparoscopic surgery...
  22. doi request reprint Comprehensive geriatric assessment in elderly breast cancer patients
    Naruto Taira
    Department of Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita ku, Japan
    Breast Cancer 17:183-9. 2010
    ..A prospective investigation of the CGA as an outcome index in elderly breast cancer patients is required to address these issues...
  23. ncbi request reprint Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors
    Megumi Inada-Inoue
    Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8560, Japan
    Cancer Chemother Pharmacol 73:673-83. 2014
    ..A phase 1 study of pazopanib alone or in combination with lapatinib was conducted to assess the safety, tolerability, and pharmacokinetics of these oral tyrosine kinase inhibitors in Japanese patients with solid tumors...
  24. ncbi request reprint Feasibility of intraoperative radiation therapy for early breast cancer in Japan: a single-center pilot study and literature review
    Masataka Sawaki
    Department of Breast Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    Breast Cancer 21:415-22. 2014
    ..Thus, this prospective single-center study aimed to test the feasibility of IORT at a single dose of 21 Gy in Japanese breast cancer patients...